Tech Company Financing Transactions

Suzhou Abogen Biosciences Funding Round

5Y Capital, SoftBank Vision Fund and Chimera Partners participated in a $300 million capital raise for Suzhou Abogen Biosciences. The funding round was announced on 11/30/2021.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

B1-501 218 Xinghu Ave. Biobay
Suzhou Jiangsu, 215123
China

Phone

Undisclosed

Website

www.abogenbio.com

Email Address

[email protected]

Overview

Abogen is a clinical-stage biotechnology company advancing mRNA-based therapeutics for the treatment of cancer and infectious diseases. Since its establishment in January 2019, Abogen has developed its own mRNA technology platform and proprietary delivery system which empowers the development of a series of drug product candidates.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Bo Ying

        

Chief Financial Officer

Yan Zhang

        

Chief Medical Officer

Hongxia Zheng

        

Browse more venture capital transactions:

Prev: 11/30/2021: Tegus venture capital transaction
Next: 11/30/2021: Vauban Technologies venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to record all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary